hypertension

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathstroke (fatal and non fatal)

angioplasty

not classified
EMMA, 1998     angioplastymedical therapynegative
SNRASCG, 1998   angioplastymedical therapyExploratory negative-40%-70%
DRASTIC, 2000     angioplastymedical therapyExploratory negative
ASTRAL, 2009     angioplastymedical therapyRisk of bias negative-2%6%
STAR, 2009   angioplastymedical therapyRisk of bias negative-1%-100%
NITER, 2009   angioplastymedical therapynegative-14%-36%

angiotensin-receptor blockers

not classified
Suzuki, 2008     ARBscontrolRisk of bias negative -34%-25%
Ruilope, 2010   LCZ696placeboLow risk of bias -
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias negative 3%83%
VALUE, 2004      NCTvalsartanamlodipineLow risk of bias suggesting 2%14%
DETAIL, 2004     telmisartanenalaprilLow risk of bias negative8%8%
OSCAR, 2011      NCTolmesartan 40 mgolmesartan 20 mg plus a calcium-channel blockerRisk of bias negative
candesartan
Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%-42%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%-11%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%-8%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-23%
HIJ-CREATE, 2009     Candesartanusual careRisk of bias -
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%27%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting
captopril
VALIANT/Val+Cap, 2003       Valsartan + captoprilCaptoprilLow risk of bias negative-1%-13%
irbesartan
IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%6%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias -
LIFE, 2002     losartanatenololLow risk of bias suggesting -11%-25%
ELITE, 1997     LosartanCaptoprilLow risk of bias suggesting-44%40%
ELITE-II, 2000     LosartanCaptoprilLow risk of bias negative12%63%
OPTIMAAL, 2001     LosartanCaptoprilRisk of bias negative 11%6%
ramipril
ONTARGET/Tel+Ram, 2008     Telmisartan + ramiprilRamiprilLow risk of bias negative6%-7%
telmisartan
PROPHESS, 2008      NCTtelmisartanplaceboLow risk of bias negative2%-5%
DETAIL, 2004     TelmisartanEnalaprilLow risk of bias negative8%8%
ONTARGET/Tel, 2008     TelmisartanRamiprilLow risk of bias negative-2%-9%
valsartan
VALIANT/Val, 2003       ValsartanCaptoprilLow risk of bias negative2%-15%

anti hypertensive agents

not classified
Suzuki, 2008     ARBscontrolRisk of bias negative -34%-25%
HOPE (diabetic subgroup), 2000       ACE inhibitorsplaceboLow risk of bias suggesting -24%-32%
CASTEL (subgroup ), 1994   beta-blockers + diureticsplacebonegative-8%-9%
STOP (subgroup ), 1991     beta-blockers or diureticsplaceboLow risk of bias negative27%16%
DORADO-AC   darusentanplacebo -
DORADO, 2009    NCTdarusentanplaceboLow risk of bias -
USPHS, 1977   diuretic and rauwolfia serpentinaplaceboLow risk of bias negative
MRC old, 1992   hydrochlorothiazide + amilorideplacebosuggesting -13%-31%
Ruilope, 2010   LCZ696placeboLow risk of bias -
ACCORD (blood pressure), 2010          NCTintensiveusualRisk of bias suggesting5%-42%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias negative 3%83%
NAGOYA HEART, 2011      NCTvalsartanamlodipineRisk of bias negative
VALUE, 2004      NCTvalsartanamlodipineLow risk of bias suggesting 2%14%
ACCOMPLISH (diabetic subgroup), 2010        NCTbenazepril + amlodipinebenazepril + hydrochlorothiazideLow risk of bias suggesting-16%-9%
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000       ACE inhibitorcalcium-channel blockerExploratory negative 14%16%
NORDIL (diabetic subgroup), 2000     diltiazemdiuretic and/or beta-blockerExploratory negative7%7%
STOP-2 (ACEI, diabetic subgroup), 2000       ACE inhibitordiuretic or beta-blockerExploratory negative-12%-12%
STOP-2 (CCB, diabetic subgroup), 2000       calcium-channel blockerdiuretic or beta-blockerExploratory negative-21%-20%
STOP-2 (CCB vs diurectic or beta-blocker), 1999     felopidine or israpidinediuretic or beta-blockersuggesting-1%-12%
DETAIL, 2004     telmisartanenalaprilLow risk of bias negative8%8%
OSCAR, 2011      NCTolmesartan 40 mgolmesartan 20 mg plus a calcium-channel blockerRisk of bias negative
AASK (amlodipine vs ramipril), 2002     amlodipineramiprilLow risk of bias negative-10%
aliskiren
ACCELERATE, 2011    NCTaliskiren amlodipine -
AVOID, 2008      NCTaliskirenplaceboLow risk of bias negative-100%
Schmieder (vs HCTZ), 2009     aliskirenhydrochlorothiazideLow risk of bias negative
ALLAY, 2009      NCTaliskirenlosartanExploratory negative
Andersen, 2008     aliskirenramiprilLow risk of bias -
amlodipine
IDNT (amlodipine vs PBO), 2001       amlodipineplaceboLow risk of bias negative-12%
IDNT (amlodipine vs pbo), 2001     amlodipineplaceboLow risk of bias negative-10%
Tepel et al, 2008      NCTamlodipineplaceboLow risk of bias negative-22%
ASCOT-BPLA, 2005     amlodipineatenololRisk of bias suggesting-10%-23%
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002       amlodipinechlorthalidoneLow risk of bias negative-4%-11%
ALLHAT (CCB vs diu), 2002     amlodipinechlorthalidonenegative -4%-6%
FACET, 1997     amlodipinefosinoprilRisk of bias suggesting-19%147%
ACCOMPLISH, 2008        NCTamlodipine plus benazeprilhydrochlorothiazide plus benazeprilLow risk of bias suggesting-10%-16%
ALLHAT (CCB vs ACEI), 2002     amlodipinelisinoprilsuggesting-4%-17%
AASK (amlodipine vs metoprolol), 2002     amlodipinemetoprololnegative-30%
atenolol
Coope, 1986   atenololcontrol suggesting-3%
Coope (subgroup ), 1986   atenololcontrolLow risk of bias negative-100%
MRC old (vs placebo), 1992   atenololplaceboLow risk of bias negative6%
MRC I (vs placebo), 1985   atenololplaceboLow risk of bias suggesting-7%
Dutch TIA, 1993   atenololplaceboLow risk of bias suggesting12%
TEST, 1995   atenololplacebonegative-20%
MRC I (vs diuretics), 1985   atenololbendroflumethiazideLow risk of bias negative 22%
MRC old (vs diuretics), 1992   atenololhydrochlorothiazide+amilorideLow risk of bias negative 22%
candesartan
Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%-42%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%-11%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%-8%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-23%
TROPHY, 2006      NCTcandesartanplaceboLow risk of bias suggesting
HSCS, 1974   deserpidine +methylclothiazideplaceboLow risk of bias negative2%-17%
Takahashi et al, 2006     candesartanusual caresuggesting-100%
Suzuki et al, 2008     candesartanusual caresuggesting-34%
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%27%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting
captopril
UKPDS 38, 1998     captopril or atenololcontrolExploratory suggesting -17%-42%
UKPDS 39, 1998     captoprilatenololExploratory negative 14%38%
CAPP (diabetic subgroup), 1999       captoprildiuretic and/or beta-blockersExploratory suggesting -46%3%
UKPDS-HDS, 1998       captoprildiuretic or beta-blockernegative14%11%
CAPPP, 1999     captoprildiuretic or beta-blockerRisk of bias negative -3%28%
carvedilol
Cice et al, 2003     carvedilolplacebosuggesting
Nakao et al, 2007   carvedilolplacebo -
chlorthalidone
SHEP (diabetic subgroup), 1996   chlorthalidoneplaceboLow risk of bias suggesting -26%-26%
VA-NHLBI, 1977   chlorthalidoneplacebonegative+Infini%
SHEP, 1991      NCTchlorthalidoneplaceboLow risk of bias suggesting -12%-35%
SHEP-pilot, 1989   chlorthalidoneplaceboLow risk of bias negative
SHEP-P (subgroup ), 1989   chlorthalidoneplaceboLow risk of bias suggesting+Infini%-79%
SHEP (subgroup ), 1991   chlorthalidoneplaceboLow risk of bias suggesting-7%-47%
diltiazem
NORDIL, 2000     diltiazemdiuretic or beta-blockersuggesting2%-18%
enalapril
ANBP2, 2003     enalaprildiureticsRisk of bias negative-7%